Intas completes deal
Intas Pharmaceuticals completes deal to acquire Actavis UK & Ireland generics businesses.
Read More
Newsroom
Imatinib Accord Launch
Accord Healthcare launches Imatinib Accord 100 mg and 400 mg in the UK.
Read MoreIntas recent acquisition
Intas Pharmaceuticals acquires the generics business of Actavis in the UK & Ireland
Read MoreAripiprazole Accord Launch
Accord Healthcare is delighted to announce the launch of Aripiprazole Accord, generic version of Abilify®. The product is available in 5, 10, 15 and 30 mg presentations in packs of 28 tablets.
Read MoreClinigen Group Extends Exclusive Agreement with Accord Healthcare to Supply Anti-Cancer Drug Capecitabine into Clinical Trials in Europe
Burton-on-Trent, UK – 14 January 2014 - Clinigen Group plc (AIM: CLIN) today announced that its Clinical Trials Supply business (Clinigen CTS) has extended its exclusive European Union (EU) clinical trial distribution agreement with Accord Healthcare (‘Accord’), to include capecitabine, an orally administered chemotherapeutic tablet.
Read MoreClinigen Group extends agreement to exclusively supply clinical trials with Accord Healthcare’s EU Oncology Products
Burton-on-Trent, UK – 20 June 2013 - Clinigen Group plc (‘Clinigen’ or the ‘Group’) (AIM: CLIN) today announced that Clinigen Clinical Trial Supply (‘CTS’) has extended its exclusive clinical trial distribution agreement with Accord Healthcare (‘Accord’), to supply clinical trials with Accord’s European injectable oncology drug portfolio for a further two years.
Read MoreAccord Healthcare Ltd. has successfully resolved the case against AstraZeneca relating to the validity of the patent covering quetiapine ER (Seroquel®
A Judgment in the case was handed down by the Court of Appeal on the 30th of April and confirms the decision of the UK High Court in March 2012 that AstraZeneca’s patent is invalid, allowing Accord Healthcare UK to launch its generic version of Seroquel®.
Read More